Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%. The rise in guidance was due to the strong momentum of NVS' key drugs and its upcoming launches. Shares of Novartis have risen 4% year to date compared with the industry's growth of 4.8%. Image Source: Zacks Investment Research For 2024-2029, sales are expected to witness a CAGR of 5%. NVS stated that it remains on track to deliver core operating income margin of 40%+ by 2027, benefiting from continued strong sales growth and productivity improvements. The rise in the mid-term outlook was driven by an increase in peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio. NVS expects strong momentum in its business with eight key drugs anticipated to generate $3-$8 billion in peak sales. The company projects 15 submission-enabling readouts in the coming years to further bolster its growth profile. In the long term, NVS has identified more than 30 assets in the pipeline to
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Novartis acquires Kate Therapeutics to advance gene therapies [Yahoo! Finance]Yahoo! Finance
- Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director [Yahoo! Finance]Yahoo! Finance
- Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential' will drive long-term growth [Fortune]Fortune
- BerGenBio Appoints Olav Hellebø as CEO [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website